Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States.

Challenge

IV bisphosphonate initiation patterns in multiple myeloma patients—including the clinical factors that predict guideline-concordant versus non-concordant initiation—had not been systematically characterized in a large real-world US oncology population.

Solution

Target RWE researchers analyzed real-world oncology data to describe patterns and predictors of IV bisphosphonate initiation in multiple myeloma, characterizing demographic, clinical, and practice-level factors associated with treatment initiation rates.

Impact

Identifying predictors of IV bisphosphonate initiation in multiple myeloma provides oncology drug development partners with evidence for targeting quality improvement efforts and designing interventions to increase guideline-concordant bone health management.